Tocilizumab and COVID-19: Timing of Administration and Efficacy
Elevated concentrations of interleukin-6 have been demonstrated to be an important key factor in COVID-19 host immune impairment. It represents an important prognostic factor of harm associated with COVID-19 infection by stimulating a vigorous proinflammatory response, leading to the so-called “cytokine storm”. Therefore, immunomodulatory interventions targeting interleukin-6 receptor antagonism have been investigated as potential treatments to counterbalance the host immune dysregulation and to support the advantageous effects of corticosteroids. Tocilizumab is a recombinant humanized monoclonal antibody that has gained much interest during the COVID-19 pandemic as an interleukin-6 receptor antagonist. Various early observational studies have reported beneficial effects of tocilizumab. Moreover, consequent randomized controlled trials have subsequently shown significant positive results about tocilizumab efficacy and safety, focusing on outcomes like mortality, risk of intensive care unit admission, and the need for mechanical ventilation, while others presented conflicting findings. In this review, we first described the pathophysiology of COVID-19 infection while highlighting the role of interleukin-6. Furthermore, we also discussed the non-conclusive evidence about tocilizumab to be used as the standard of care therapy for all patients with COVID-19 pneumonia, as well as its beneficial effects in selected patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in Pharmacology - 13(2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emna Abidi [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Acute respiratory distress syndrome |
|---|
| doi: |
10.3389/fphar.2022.825749 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ013931121 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ013931121 | ||
| 003 | DE-627 | ||
| 005 | 20230310062042.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2022.825749 |2 doi | |
| 035 | |a (DE-627)DOAJ013931121 | ||
| 035 | |a (DE-599)DOAJ80259940797b4a65ae792576df172842 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Emna Abidi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab and COVID-19: Timing of Administration and Efficacy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Elevated concentrations of interleukin-6 have been demonstrated to be an important key factor in COVID-19 host immune impairment. It represents an important prognostic factor of harm associated with COVID-19 infection by stimulating a vigorous proinflammatory response, leading to the so-called “cytokine storm”. Therefore, immunomodulatory interventions targeting interleukin-6 receptor antagonism have been investigated as potential treatments to counterbalance the host immune dysregulation and to support the advantageous effects of corticosteroids. Tocilizumab is a recombinant humanized monoclonal antibody that has gained much interest during the COVID-19 pandemic as an interleukin-6 receptor antagonist. Various early observational studies have reported beneficial effects of tocilizumab. Moreover, consequent randomized controlled trials have subsequently shown significant positive results about tocilizumab efficacy and safety, focusing on outcomes like mortality, risk of intensive care unit admission, and the need for mechanical ventilation, while others presented conflicting findings. In this review, we first described the pathophysiology of COVID-19 infection while highlighting the role of interleukin-6. Furthermore, we also discussed the non-conclusive evidence about tocilizumab to be used as the standard of care therapy for all patients with COVID-19 pneumonia, as well as its beneficial effects in selected patients. | ||
| 650 | 4 | |a COVID-19 infection | |
| 650 | 4 | |a SARS-CoV-2 infection | |
| 650 | 4 | |a cytokine storm | |
| 650 | 4 | |a interleukine -6 receptor antagonist | |
| 650 | 4 | |a tocilizumab | |
| 650 | 4 | |a acute respiratory distress syndrome | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Wasim S. El Nekidy |e verfasserin |4 aut | |
| 700 | 0 | |a Wasim S. El Nekidy |e verfasserin |4 aut | |
| 700 | 0 | |a Eman Alefishat |e verfasserin |4 aut | |
| 700 | 0 | |a Eman Alefishat |e verfasserin |4 aut | |
| 700 | 0 | |a Eman Alefishat |e verfasserin |4 aut | |
| 700 | 0 | |a Nadeem Rahman |e verfasserin |4 aut | |
| 700 | 0 | |a Nadeem Rahman |e verfasserin |4 aut | |
| 700 | 0 | |a Georg A. Petroianu |e verfasserin |4 aut | |
| 700 | 0 | |a Rania El-Lababidi |e verfasserin |4 aut | |
| 700 | 0 | |a Jihad Mallat |e verfasserin |4 aut | |
| 700 | 0 | |a Jihad Mallat |e verfasserin |4 aut | |
| 700 | 0 | |a Jihad Mallat |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Pharmacology |d Frontiers Media S.A., 2010 |g 13(2022) |w (DE-627)DOAJ000099732 |x 16639812 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2022.825749 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/80259940797b4a65ae792576df172842 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fphar.2022.825749/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1663-9812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 | ||